[FATE] Fate Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 2.83 Change: 0.05 (1.8%)
Ext. hours: Change: 0 (0%)

chart FATE

Refresh chart

Strongest Trends Summary For FATE

FATE is in the medium-term down -38% below S&P in 1 year. In the long-term up 131% in 3 years and up 553% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person?s lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person?s lifespan. The company?s lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dy

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-60.2% ROE-126.04% ROI
Current Ratio6.67 Quick Ratio Long Term Debt/Equity Debt Ratio0.3
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70 K Cash From Investing Activities-450 K Cash From Operating Activities-6.38 M Gross Profit
Net Profit-7.88 M Operating Profit-7.32 M Total Assets44.49 M Total Current Assets42.79 M
Total Current Liabilities6.41 M Total Debt19.67 M Total Liabilities23.24 M Total Revenue
Technical Data
High 52 week22.5 Low 52 week8.75 Last close14.75 Last change4.39%
RSI34.85 Average true range0.92 Beta1.36 Volume25.46 K
Simple moving average 20 days-5.08% Simple moving average 50 days-13.1% Simple moving average 200 days-11.64%
Performance Data
Performance Week-1.14% Performance Month-18.46% Performance Quart-33.74% Performance Half-9.79%
Performance Year26.83% Performance Year-to-date14.96% Volatility daily3.56% Volatility weekly7.96%
Volatility monthly16.31% Volatility yearly56.5% Relative Volume139.39% Average Volume776.43 K
New High New Low


2020-05-20 08:00:10 | Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

2020-05-15 06:18:00 | Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock

2020-05-15 06:18:00 | Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock

2020-05-12 16:30:54 | Fate Therapeutics Inc FATE Q1 2020 Earnings Call Transcript

2020-05-12 13:40:00 | Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering

2020-05-12 09:30:48 | Edited Transcript of FATE earnings conference call or presentation 11-May-20 9:00pm GMT

2020-05-11 17:15:09 | Fate Therapeutics FATE Reports Q1 Loss, Tops Revenue Estimates

2020-05-11 16:01:10 | Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress

2020-05-08 08:46:12 | Should You Buy Fate Therapeutics FATE Ahead of Earnings?

2020-05-05 21:18:49 | Were Hedge Funds Right About Fate Therapeutics Inc FATE?

2020-05-05 16:01:10 | Fate Therapeutics Announces Changes to its Board of Directors

2020-05-04 16:01:10 | Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2020 Financial Results

2020-05-04 09:38:01 | Why Earnings Season Could Be Great for Fate Therapeutics FATE

2020-04-30 08:33:20 | 3 Monster Growth Stocks With Still Plenty of Gas in the Tank

2020-04-29 07:11:00 | Is Fate Therapeutics a Buy?

2020-04-28 16:30:10 | Fate Therapeutics Announces Preclinical Data Presentation of Novel CAR MICA/B Cell-based Cancer Immunotherapy Program at the 2020 ASGCT Annual Meeting

2020-04-28 12:33:04 | Fate Therapeutics FATE Expected to Beat Earnings Estimates: Should You Buy?

2020-04-14 09:13:01 | Top Ranked Momentum Stocks to Buy for April 14th

2020-04-10 12:00:04 | Fate Therapeutics FATE is a Great Momentum Stock: Should You Buy?

2020-04-08 11:30:03 | Is Fate Therapeutics FATE Stock Outpacing Its Medical Peers This Year?

2020-04-08 10:05:02 | Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More

2020-04-08 10:04:02 | Is Fate Therapeutics FATE Stock a Solid Choice Right Now?

2020-04-06 09:08:01 | Fate Therapeutics FATE Looks Good: Stock Adds 8.9% in Session

2020-04-04 09:07:58 | Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. NASDAQ:FATE Revenue Forecasts By 13%

2020-04-03 18:34:00 | 7 Biotech Stocks to Buy for a Post-Pandemic World

2020-04-03 10:57:02 | Fate Therapeutics Surges on Immunotherapy Deal With J&J

2020-04-03 07:36:23 | The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO

2020-04-02 17:42:14 | Small Biotech Jumps On $100 Million Cancer Deal With Pharma Giant J&J

2020-04-02 16:46:10 | Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies

2020-04-02 16:45:10 | Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update

2020-03-22 13:36:05 | Edited Transcript of FATE earnings conference call or presentation 2-Mar-20 10:00pm GMT

2020-03-17 10:24:02 | Are Options Traders Betting on a Big Move in Fate Therapeutics FATE Stock?

2020-03-02 17:15:10 | Fate Therapeutics FATE Reports Q4 Loss, Tops Revenue Estimates

2020-03-02 16:01:10 | Fate Therapeutics Reports Fourth Quarter 2019 Financial Results and Operational Progress with 2020 Outlook

2020-02-29 14:52:43 | The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

2020-02-26 08:00:10 | Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2019 Financial Results

2020-02-25 12:30:05 | Analysts Estimate Fate Therapeutics FATE to Report a Decline in Earnings: What to Look Out for

2020-02-07 08:00:10 | Fate Therapeutics to Present at Upcoming Investor Conferences

2020-02-05 11:52:05 | Steven Cohen Renews His Interest in Verastem

2020-01-16 06:15:36 | Fate Therapeutics NASDAQ:FATE Shareholders Have Enjoyed A Whopping 682% Share Price Gain

2020-01-13 08:00:10 | Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood

2020-01-03 10:44:20 | 3 Top Drug Stocks to Own In 2020

2019-12-11 09:41:02 | Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

2019-12-10 09:52:06 | Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

2019-12-10 09:48:02 | Fate FATE Announces Encouraging Data on Immunotherapies

2019-12-10 09:07:02 | Company News for Dec 10, 2019

2019-12-09 16:19:28 | Here Are The Winners From The Year's Biggest Hematology Meeting

2019-12-09 14:16:51 | Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook

2019-12-09 11:04:00 | Fate Therapeutics' stock rises on early-stage cancer drug data

2019-12-08 19:28:36 | Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc FATE